File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Gestational trophoblastic disease

TitleGestational trophoblastic disease
Authors
KeywordsGestational trophoblastic disease
Gestational trophoblastic neoplasia
Mole
Placental-site trophoblastic tumour
Staging
Treatment
Issue Date2006
PublisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/curobgyn
Citation
Current Obstetrics And Gynaecology, 2006, v. 16 n. 2, p. 93-99 How to Cite?
AbstractGestational trophoblastic disease is a disease of the proliferative trophoblastic allograft and includes partial mole (PM), complete hydatidiform mole (CM), invasive and metastatic mole, choriocarcinoma, placental-site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT). Suction evacuation is recommended to terminate CM or PM. PM or CM should be monitored with serum human chorionic gonadotrophin, and effective contraception should be advised for at least 6 months. About 10-20% of patients with molar pregnancy may progress to gestational trophoblastic neoplasia (GTN) which requires chemotherapy. At the 2000 International Federation of Obstetrics and Gynecology (FIGO) meeting, recommendations were made on the criteria for diagnosing GTN and on methods of investigation. Staging was revised to include a modified World Health Organization risk score. The first-line chemotherapy for low-risk GTN is methotrexate and, for high-risk GTN, EMA-CO is recommended. In PSTT and ETT, surgery plays a more important role than chemotherapy. Referral of patients to a centre with experience in treating GTN is important to ensure a good outcome. © 2006.
Persistent Identifierhttp://hdl.handle.net/10722/87189
ISSN

 

DC FieldValueLanguage
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorChan, KKLen_HK
dc.contributor.authorTam, KFen_HK
dc.date.accessioned2010-09-06T09:26:28Z-
dc.date.available2010-09-06T09:26:28Z-
dc.date.issued2006en_HK
dc.identifier.citationCurrent Obstetrics And Gynaecology, 2006, v. 16 n. 2, p. 93-99en_HK
dc.identifier.issn0957-5847en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87189-
dc.description.abstractGestational trophoblastic disease is a disease of the proliferative trophoblastic allograft and includes partial mole (PM), complete hydatidiform mole (CM), invasive and metastatic mole, choriocarcinoma, placental-site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT). Suction evacuation is recommended to terminate CM or PM. PM or CM should be monitored with serum human chorionic gonadotrophin, and effective contraception should be advised for at least 6 months. About 10-20% of patients with molar pregnancy may progress to gestational trophoblastic neoplasia (GTN) which requires chemotherapy. At the 2000 International Federation of Obstetrics and Gynecology (FIGO) meeting, recommendations were made on the criteria for diagnosing GTN and on methods of investigation. Staging was revised to include a modified World Health Organization risk score. The first-line chemotherapy for low-risk GTN is methotrexate and, for high-risk GTN, EMA-CO is recommended. In PSTT and ETT, surgery plays a more important role than chemotherapy. Referral of patients to a centre with experience in treating GTN is important to ensure a good outcome. © 2006.en_HK
dc.languageengen_HK
dc.publisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/curobgynen_HK
dc.relation.ispartofCurrent Obstetrics and Gynaecologyen_HK
dc.subjectGestational trophoblastic diseaseen_HK
dc.subjectGestational trophoblastic neoplasiaen_HK
dc.subjectMoleen_HK
dc.subjectPlacental-site trophoblastic tumouren_HK
dc.subjectStagingen_HK
dc.subjectTreatmenten_HK
dc.titleGestational trophoblastic diseaseen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0957-5847&volume=16&issue=2&spage=93&epage=99&date=2006&atitle=Gestational+Trophoblastic+Diseaseen_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.emailChan, KKL:kklchan@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.identifier.authorityChan, KKL=rp00499en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.curobgyn.2006.01.005en_HK
dc.identifier.scopuseid_2-s2.0-33646480922en_HK
dc.identifier.hkuros131842en_HK
dc.identifier.volume16en_HK
dc.identifier.issue2en_HK
dc.identifier.spage93en_HK
dc.identifier.epage99en_HK
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridChan, KKL=8655666700en_HK
dc.identifier.scopusauthoridTam, KF=7201692816en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats